首页|抗血小板药物的质量研究进展

抗血小板药物的质量研究进展

扫码查看
抗血小板药物近年来呈现蓬勃发展的态势,其质量控制标准也在不断发展和完善.本综述基于《中国人民共和国药典》2020年版(ChP 2020)、《美国药典》43版(USP 43)、《日本药典》17版(JP 17)等国内外及相关指导原则等参考资料,全面归纳了抗血小板药物在药典中的收录情况,对常见的抗血小板药物的质量控制方法进行总结,对含量测定和体内药物分析方法等项目进行全面分析,期望为抗血小板药物的研究与开发提供参考.
Research Progress on the Quality of Antiplatelet Drugs
In recent years,antithrombotic drugs have been increasingly developed,and the related quality control standards have also been improved.The inclusion of antithrombotic drugs in these pharmacopeias was summarized based on the 2020 edition of the People's Republic of China Pharmacopoeia(ChP 2020),the 43 edition of the United States Pharmacopeia(USP 43),the 17 edition of the Japanese Pharmacopeia(JP 17),and pertinent domestic and foreign guidelines.In addition,the elements of quality control,such as assay and in vivo drug analysis methods,were specifically included to serve as a point of reference for the research and development of quality control methods for antithrombotic drugs.

antiplatelet drugscontent determination methodin vivo drug analysisexamination of relevant substancesphenothiopyridine drugs

赵欢、张春然、王宇驰、王瑛瑛、张静霞、李诗媛

展开 >

成都大学,成都 610106

四川大学华西药学院,成都 610065

抗血小板药物 含量测定方法 体内药物分析 有关物质检查 吩噻吡啶药物

2024

国外医药(抗生素分册)
中国医药集团总公司四川抗菌素工业研究所,中国医学科学院医药生物技术研究所

国外医药(抗生素分册)

影响因子:0.852
ISSN:1001-8751
年,卷(期):2024.45(1)
  • 15